Form 4: Rafael Bejar Reports Aptose Biosciences Share Changes

Rafael Bejar, former SVP & Chief Medical Officer of Aptose Biosciences Inc., has reported changes in his beneficial ownership of company securities.

Summary

• Rafael Bejar, former SVP & Chief Medical Officer of Aptose Biosciences Inc., has filed a Form 4 detailing transactions related to his beneficial ownership of the company's securities.
• The filing indicates a disposition of 244 common shares on June 30, 2026, at a price of $1.72 per share, converted from C$2.41.
• This disposition was part of a business arrangement agreement where a subsidiary of Hammi Pharmaceuticals Co. Inc. acquired all outstanding shares of Aptose Biosciences.
• The filing also details various stock options held by Bejar, including employee stock options and performance stock options, with different exercise prices and vesting schedules.
• These options are subject to adjustments due to previous reverse stock splits.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, primarily reporting on past transactions related to an acquisition rather than providing new performance data or future guidance.

Positives

• The disposition of shares was part of a pre-approved business arrangement, suggesting a structured and transparent exit for the reporting person.
• The reporting person continues to hold various stock options, indicating ongoing potential future equity participation, albeit subject to performance and vesting.
• The filing clearly outlines the terms of the acquisition by Hammi Pharmaceuticals, providing clarity on the transaction for stakeholders.

Negatives

• The disposition of common shares indicates a reduction in direct beneficial ownership by a key former executive.
• The conversion of Canadian dollars to US dollars at a specific exchange rate (C$1.4 = US$1.00) might represent a less favorable outcome for the reporting person if the actual market rate was higher at the time of conversion.
• The performance stock options are contingent on specific performance criteria, meaning their ultimate value is not guaranteed.

Risks

• The acquisition by Hammi Pharmaceuticals Co. Inc. introduces a change in control, which could lead to strategic shifts or integration challenges for Aptose Biosciences.
• The performance stock options carry the risk of not meeting the specified performance criteria, rendering them worthless.
• Reverse stock splits, as mentioned in the remarks, can sometimes be perceived negatively by the market, potentially impacting investor sentiment.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance from management regarding future financial performance. The future outlook for Aptose Biosciences is now intrinsically linked to the integration and strategy of Hammi Pharmaceuticals Co. Inc. following the acquisition.

Management Comments

• The disposition of shares was made pursuant to a board, shareholder, and court-approved business arrangement agreement.
• The reporting person's options are subject to adjustment as a result of the issuer's previous reverse stock splits.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. This particular filing reflects a significant event for Aptose Biosciences: an acquisition by Hammi Pharmaceuticals. Such acquisitions often lead to changes in executive roles and equity holdings, as seen here with Rafael Bejar's reported transactions.

Management Changes

Legal Proceedings

• The share disposition was made pursuant to a court-approved business arrangement agreement.

Related Party Transactions

• The disposition of 244 common shares was part of a business arrangement agreement with Hammi Pharmaceuticals Co. Inc., a related party through the acquisition.

Stakeholder Impact

• Shareholders of Aptose Biosciences have had their shares acquired by Hammi Pharmaceuticals at C$2.41 per share.
• Employees of Aptose Biosciences may experience changes in roles, responsibilities, and company culture following the acquisition.
• Creditors and suppliers will now be dealing with the acquiring entity, Hammi Pharmaceuticals.

Next Steps

• Integration of Aptose Biosciences into Hammi Pharmaceuticals Co. Inc.
• Potential future transactions or adjustments related to outstanding stock options.
• Monitoring of Aptose Biosciences' performance under new ownership.

Key Dates

Keywords

Form 4, SEC Filing, Beneficial Ownership, Aptose Biosciences, Rafael Bejar, Stock Options, Share Disposition, Acquisition, Hammi Pharmaceuticals, Executive Transactions